BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Our proprietary human-first platform encompasses >65M molecular measurements spanning 45+ years of human aging, and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. We currently have three clinical programs in our growing portfolio–two first in class and two first in indication–for immune aging and muscle aging. Ultimately, our mission is to develop therapies that change the nature of aging and provide patients with years more healthy time. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.
For additional information about BioAge, visit the company’s website at www.bioagelabs.com.
BioAge offers a comprehensive compensation package, as well as generous paid time off in addition to company-observed holidays. We provide comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, along with a 401(k) retirement savings plan which includes matching employer contributions. We also pride ourselves in giving employees many opportunities for career development including a generous annual budget for continued learning, a direct and open-door environment, and a dedication to training and skill development.
At BioAge, everyone matters and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as to the letter of all applicable laws and regulations.
For additional information about BioAge, visit the company’s website at www.bioagelabs.com.
BioAge offers a comprehensive compensation package, as well as generous paid time off in addition to company-observed holidays. We provide comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, along with a 401(k) retirement savings plan which includes matching employer contributions. We also pride ourselves in giving employees many opportunities for career development including a generous annual budget for continued learning, a direct and open-door environment, and a dedication to training and skill development.
At BioAge, everyone matters and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as to the letter of all applicable laws and regulations.
Location: United States, California, Richmond
Employees: 51-200
Total raised: $270.9M
Founded date: 2015
Investors 9
Funding Rounds 3
Date | Series | Amount | Investors |
13.02.2024 | Series D | $170M | - |
07.12.2020 | Series C | $90M | - |
29.07.2017 | Series A | $10.9M | - |
Mentions in press and media 21
Date | Title | Description |
25.09.2024 | BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials | BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic. The Eli Lilly-partnered biotech revealed i... |
23.09.2024 | Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging | 13 Shares Email Facebook Twitter LinkedIn We are all getting older. But never before have we been getting this much older. In the U.S., at least one in six people is now over the age of 65. At the same time, in most developed countries olde... |
13.09.2024 | These Female Founders And CEOs Raised The Biggest Rounds In 2024 | 6 Shares Email Facebook Twitter LinkedIn When measuring funding to startups with female founders and CEOs, the perennial takeaway is that women remain underrepresented. Last year, for instance, just 3% of U.S. funding went to startups with ... |
29.07.2024 | BioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide | Trial to evaluate weight loss efficacy of azelaprag, an oral small molecule apelin receptor agonist that mimics key biological effects of exercise STRIDES is being conducted in collaboration with Lilly’s Chorus clinical development organiza... |
13.02.2024 | BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics | February 13, 2024 08:00 AM Eastern Standard Time RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of ag... |
13.02.2024 | GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D | Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently. The frenzy around GLP-1s changed all of that, with BioAge’s profile a... |
13.02.2024 | BioAge Labs Raises $170M Series D Round | RICHMOND, CA, BioAge Labs announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments. >> Click here for more funding data on BioAge Labs >> To export BioAge Labs... |
13.02.2024 | BioAge Labs Raises $170M in Series D Financing | BioAge Labs, a Richmond, CA-based clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, raised $170M in Series D funding. The round was led by Sofinnova Invest... |
10.03.2023 | Tweekly. Выпуск 160. Бессмертие как сервис | Что сейчас растёт и как это применить 1. Бессмертие как сервис (IaaS). То, чего все хотят и боятся одновременно. 2. Цифровые клоны городов и производств — быстрая проверка «капиталоемких» гипотез. Следующий шаг - проверка жизнеспособности п... |
06.12.2022 | BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest | BioAge Labs, (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, announced positive Phase 1b clinical data for BGE-105, a highly selective, p... |
Show more